Biodel Inc (NASDAQ:BIOD)

CAPS Rating: 5 out of 5

A specialty pharmaceutical company, which focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis.

Recs

4
Player Avatar BioInvestor217 (< 20) Submitted: 9/29/2010 12:08:15 AM : Outperform Start Price: $20.56 BIOD Score: -151.05

BIOD has quietly developed an improved mixed insulin product compatible with Lantus, which would allow the “holy grail” combination fast-acting/long acting insulin to be created. They are a top pick with an FDA review date of October 30th. Price estimate by that date of $7.00-$7.50. Once approved their insulin drug would revolutionize treatment of diabetes and will be targeting a massive market. Clinical tests and trials look good, overall very good outlook.

Report this Post 2 Replies
Member Avatar ThankHedgens (69.74) Submitted: 9/29/2010 2:36:01 PM
Recs: 0

I tend to agree, this is the next big pharma play since ARNA. It should have better performance

Member Avatar XpXp (34.97) Submitted: 10/3/2010 9:22:08 AM
Recs: 0

I beliveve Linjeta will be approved on Oct 30th.
I believe that BIOD will probably trade higher into the event.
Any investor considering a position should read this article:
http://seekingalpha.com/article/225291-biodel-s-linjeta-should-overcome-the-usual-fda-approval-hurdles,
and consider the India data before investing.

Featured Broker Partners


Advertisement